Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Jerry L. Klein"'
Autor:
Ramaswamy Subramanian, Michael G. Hanna, Jerry L. Klein, Martin V. Haspel, Jacobus C.J. Stiekema, R.L. De Jager, Nicholas Pomato
Publikováno v:
Cancer Therapy with Radiolabeled Antibodies ISBN: 9781351070409
Cancer Therapy with Radiolabeled Antibodies
Cancer Therapy with Radiolabeled Antibodies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::68a25f24c0cf836ba93c4d042479bb36
https://doi.org/10.1201/9781351070409-20
https://doi.org/10.1201/9781351070409-20
Autor:
R. Subramanian, Aldo N. Serafini, H C Hoover, A Chetanneau, R Baum, A Pecking, B G Wolff, D K Goroff, G E Wynant, Jerry L. Klein, M G Hanna, A J Fischman
Publikováno v:
Journal of Clinical Oncology. 16:1777-1787
PURPOSE To assess the performance and potential clinical impact of a totally human monoclonal antibody, 88BV59 (HumaSPECT) (INTRACEL, Corp, Rockville, MD), in 202 assessable presurgical patients with recurrent, metastatic, or occult colorectal cancer
Publikováno v:
Nuclear Medicine and Biology. 22:413-423
Unmodified F(ab′) 2 and modified Fab′-BMH-Fab′ fragments of human monoclonal IgM (16.88) were compared for biodistribution and tumor localization in nude mice bearing LS-174T human colon carcinoma xenografts. Although both unmodified and modifi
Autor:
Peter K. Leichner, Ross A. Abrams, Karel A. Dicke, Jerry L. Klein, James O. Armitage, Julie M. Vose, Syed M. Quadri, Huibert M. Vriesendorp, Philip J. Bierman
Publikováno v:
Journal of Clinical Oncology. 11:698-703
PURPOSE This study was undertaken to examine the feasibility of combining radiolabeled antibody therapy with high-dose chemotherapy followed by autologous bone marrow transplantation in patients with poor-prognosis Hodgkin's disease. PATIENTS AND MET
Autor:
David S. Ettinger, Gary B. Stillwagon, E K Fishman, Jerry L. Klein, Stanley E. Order, Peter K. Leichner, Jeff Herpst, Tom Haulk
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 21:1601-1605
Previous experience using 131I anti-CEA antibody, which irradiates at a variable low dose rate in combination with a multimodality treatment program, has demonstrated acceptable toxicity and response in primary intrahepatic cholangiocarcinoma. In att
Autor:
Thomas F. Pajak, Chester Frazier, Gary B. Stillwagon, Sucha O. Asbell, J M Herpst, Ken Kopher, Jerry L. Klein, David S. Ettinger, Peter K. Leichner, Stanley E. Order, Tom Haulk, Steven Leib
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 20:953-963
A previously reported Phase I/II multimodality program for non-resectable hepatocellular cancer began with external beam-radiation and chemotherapy, followed by administration of 131I antiferritin-specific radioimmunoglobulin and led to a 48% remissi
Autor:
Peter K. Leichner, Sucha O. Asbell, Jerry L. Klein, Clare Guse, Gary B. Stillwagon, Stanley E. Order, Steven A. Leibel
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 20:65-71
The Radiation Therapy Oncology Group (RTOG) conducted a Phase I/II study in hepatocellular cancer that closed on September 9, 1987 and some results presented previously. Here, 17 patient characteristics are evaluated to identify any of prognostic sig
Autor:
Jerry L. Klein, Herbert C. Hoover, Ramaswamy Subramanian, Michael G. Hanna, Richard P. Baum, Aldo N. Serafini, John Bolton, Alan J. Fischman, Diana K. Goroff, Bruce G. Wolff, Alain Chetanneau, Gordon E. Wynant, Alain Pecking
Publikováno v:
Diseases of the colon and rectum. 41(8)
PURPOSE: The study contained herein was undertaken to evaluate the accuracy of radiolabeled human monoclonal antibody, 88BV59H21-2V67-66 (88BV59 or HumaSPECT®-Tc), in predicting disease resectability in presurgical subjects with recurrent, metastati
Autor:
F Gougeonbertrand, S Shaban, F. M. Lokiec, A Pecking, J. L. Floiras, R. L. Dejager, R Subramanian, M Hanna, M. V. Haspel, Jerry L. Klein, A Boudinet, James L. Murray
Publikováno v:
International Journal of Oncology.
Thirty-one primary breast cancer patients were evaluated by radioimmunolymphoscintigraphy (RILS) and ex vivo scintigraphy (EVS) following subcutaneous injection of human monoclonal antibody In-111-LiLo-16.88. Lymph nodes (370) were assessed by EVS, p